David M Feldser

13PUBLICATIONS
53CO-AUTHORS
Predictive and prognostic markersMolecular targetsLiquid biopsiesCarbon capture engineering (excl. sequestration)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 15, 2026
Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.

|Jun 12, 2025
The H3 K36M oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer.

Amy C Gladstein, Carson D Poltorack, Akino Mercy Charles Solomon

|Sep 20, 2023
Metastatic Competency and Tumor Spheroid Formation Are Independent Cell States Governed by RB in Lung Adenocarcinoma.

Nelson F Freeburg, Nia Peterson, Dain A Ruiz

|Jul 21, 2023
p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism.

Jonuelle Acosta, Qinglan Li, Nelson F Freeburg

|Mar 10, 2023
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling.

David M Walter, Amy C Gladstein, Katherine R Doerig

|Mar 01, 2022
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer.

Christopher W Murray, Jennifer J Brady, Mingqi Han

Pageof 3

Frequent Collaborators

6 joint publications

Amy C Gladstein

3 joint publications

Monte M Winslow

3 joint publications

Keren M Adler

2 joint publications

Nelson F Freeburg